Trial Profile
A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours; Small cell lung cancer
- Focus Therapeutic Use
- 12 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 12 Mar 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Jul 2024.
- 04 Apr 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.